Atorvastatin lipid lowering assessment survey in patients with hypercholesterolemia (ALWAYS)

Therapeutic Research

Volumn 32, Issue 12, 2011, Pages 1587-1603

  Teramoto, Tamio ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LIPID;

ARTICLE; HYPERCHOLESTEROLEMIA;

EID: 84856182792     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Thomas HE Jr, Kannel WB, Dawber TR, McNamara PM. Cholesterol-phospholipid ratio in the prediction of coronary heart disease. The Framingham Study. N Engl J Med 1966;274:701-5.
2. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial : Findings related to a priori hypotheses of the trial. JAMA 1990;263:1795-801.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease : the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
4. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. (Pubitemid 40471450)
5. The Lipid 2001;12:239-47.
6. Jpn Pharmacol Ther 2008;36:9-28.
7. Prog Med 2007;27:1159-89.
8. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) : a multicentre randomised controlled trial. Lancet 2003;5:1149-58. (Pubitemid 36398384)
9. Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Yanagisawa N, Tamura H, et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial) : a follow-up study. Atherosclerosis 2010;210:497-502.
10. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39. (Pubitemid 38924592)
11. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias : The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217:3-46.
12. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias : the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
13. Teramoto T, Kashiwagi A, Mabuchi H. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 Report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults : A Study of the Japan Lipid Assessment Program (J-LAP). Current Ther Res 2005;66:80-95.
14. Prog Med 2005;25:131-42.